How many drugs treat Streptococcal septicemia?

Drug Landscape tracks 10 marketed treatments for Streptococcal septicemia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Streptococcal septicemia?

Most recent: Cleocin T — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/streptococcal-septicemia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Streptococcal septicemia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Streptococcal septicemia (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Streptococcal septicemia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Claforan	CEFOTAXIME	Sterimax	Cephalosporin Antibacterial		1981-01-01
Cefaprin	cefapirin	Bristol-Myers Squibb	cefapirin	Sigma non-opioid intracellular receptor 1	1974-01-01
Cleocin T	CLINDAMYCIN PHOSPHATE	Pfizer	Lincosamide Antibacterial		1972-01-01
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-03-23 — Cleocin T · FDA · approved · US
2026-03-18 — Cleocin T · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 5 drugs in Streptococcal septicemia
Bristol-Myers Squibb · 2 drugs in Streptococcal septicemia
Pai Holdings Pharm · 2 drugs in Streptococcal septicemia
Generic (originally Roche) · 1 drug in Streptococcal septicemia
Generic (originally Upjohn/Pfizer) · 1 drug in Streptococcal septicemia
Pfizer · 1 drug in Streptococcal septicemia
Sterimax · 1 drug in Streptococcal septicemia
Tel-Aviv Sourasky Medical Center · 1 drug in Streptococcal septicemia
Centre Hospitalier Universitaire Vaudois · 1 drug in Streptococcal septicemia
GSK · 1 drug in Streptococcal septicemia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Streptococcal septicemia:

Cite this brief

Drug Landscape (2026). Streptococcal septicemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcal-septicemia. Accessed 2026-06-10.

Streptococcal septicemia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing